Innovation in the diagnosis and treatment of tuberculosis and tuberculosis merger HBV infection

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIh-17011870

Enrollment

Unknown

Registered

2017-07-05

Start date

2017-09-01

Completion date

Unknown

Last updated

2017-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatitis B

Interventions

study group:?dT cell adoptive immunotherapy

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-45 years old, male or female; 2. Informed consent; 3. Patient who were tested HBsAg and HBeAg positive; 4. HBV DNA loads>1 million copy/ml; 5. Liver function test alanine aminotransferase (ALT) 160 IU/L=400 IU/L; 6. No jaundice, total bilirubin is normal; 7. For patients with new onset, oral antiviral drugs limited for Sebivo.

Exclusion criteria

Exclusion criteria: 1. Pregnant women; 2. Patients Complicated with other viruses, bacteria infections and other infectious diseases; 3. With other diseases such as diabetes, cancer, hypertension, coronary heart disease, endocrine system disease, mental illness, neurological disease, vascular circulation system diseases and so on, and after clinical doctors diagnose, evaluate the immune cells are not suitable for treatment of patients; 4. Other indications that is not suitable for the treatment.

Design outcomes

Primary

Measure	Time frame
DNA load;ALT;immunologic function;HbeAg;	—

Countries

China

Contacts

Public ContactZhinan Yin

Biomedical Translational Research Institute,jinan University

1012294130@qq.com+86 020-85222787

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026